Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guerin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
journal contributionposted on 06.07.2021, 03:56 authored by Jessica da Gama DuarteJessica da Gama Duarte, Sagun ParakhSagun Parakh, Miles AndrewsMiles Andrews, Katherine Woods, Anupama Pasam, Candani Tutuka, Simone OstrouskaSimone Ostrouska, Jonathan M Blackburn, Andreas BehrenAndreas Behren, Jonathan CebonJonathan Cebon
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. The first ICI to demonstrate clinical benefit, ipilimumab, targets cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4); however, the long-term overall survival is just 22%. More than 40 years ago intralesional (IL) bacillus Calmette-Guérin (BCG), a living attenuated strain of Mycobacterium bovis, was found to induce tumor regression by stimulating cell-mediated immunity following a localized and self-limiting infection. We evaluated these two immune stimulants in combination with melanoma with the aim of developing a more effective immunotherapy and to assess toxicity. In this phase I study, patients with histologically confirmed stage III/IV metastatic melanoma received IL BCG injection followed by up to four cycles of intravenous ipilimumab (anti-CTLA-4) (ClinicalTrials.gov number NCT01838200). The trial was discontinued following treatment of the first five patients as the two patients receiving the escalation dose of BCG developed high-grade immune-related adverse events (irAEs) typical of ipilimumab monotherapy. These irAEs were characterized in both patients by profound increases in the repertoire of autoantibodies directed against both self- and cancer antigens. Interestingly, the induced autoantibodies were detected at time points that preceded the development of symptomatic toxicity. There was no overlap in the antigen specificity between patients and no evidence of clinical responses. Efforts to increase response rates through the use of novel immunotherapeutic combinations may be associated with higher rates of irAEs, thus the imperative to identify biomarkers of toxicity remains strong. While the small patient numbers in this trial do not allow for any conclusive evidence of predictive biomarkers, the observed changes warrant further examination of autoantibody repertoires in larger patient cohorts at risk of developing irAEs during their course of treatment. In summary, dose escalation of IL BCG followed by ipilimumab therapy was not well tolerated in advanced melanoma patients and showed no evidence of clinical benefit. Measuring autoantibody responses may provide early means for identifying patients at risk from developing severe irAEs during cancer immunotherapy.
We thank the Ludwig Institute for Cancer Research (study sponsor) and Bristol-Myers Squibb for funding this clinical study, as well as all patients who volunteered to participate. We also thank Rodica Stan, Tina Cavicchiolo, and Noel Micallef for their essential contributions to the clinical trial. JD is supported by a Tour de Cure Scott Canner Young Research Grant. MA is supported by a NHMRC CJ Martin Fellowship (#1148680). JB is supported by a Research Chair Grant from the South African National Research Foundation (#64760). AB is supported by a Mid-Career Research Fellowship from the Victorian Cancer Agency (#17019). The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational Infrastructure Support Program.
JournalFrontiers in Immunology
Pagination9p. (p. 1-9)
PublisherFrontiers Research Foundation
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineImmunologymelanomabacillus Calmette-Guerinipilimumabimmune-related adverse eventsprotein microarraysBCG IMMUNOTHERAPYACTIVE IMMUNOTHERAPYMALIGNANT-MELANOMACANCERTHERAPYAUTOIMMUNITYSURVIVALTRIALBIOMARKERSANTIGENSHumansMycobacterium bovisMelanomaSkin NeoplasmsNeoplasm MetastasisCancer VaccinesAutoantibodiesNeoplasm StagingImmunotherapyCombined Modality TherapyAdultAgedMiddle AgedFemaleMaleCTLA-4 AntigenIpilimumabbacillus Calmette–Guerin